Jain Swati, Das Debanjana, Mukherjee Abhiyanta, Roy Ipsita
Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Punjab, 160 062, India.
Mol Neurobiol. 2025 May 24. doi: 10.1007/s12035-025-05075-1.
Hexanucleotide (GGGGCC) repeat expansion in non-coding region of C9ORF72 is the main genetic cause of amyotrophic lateral sclerosis-frontotemporal dementia (ALS-FTD). Gain of toxic function, via RNA or proteins, or loss of function via haploinsufficiency, are probable mechanisms of disease progression. Expanded GGGGCC repeat codes for dipeptide repeat (DPR) proteins which form inclusions in the brain. Among all the dipeptides, aggregates formed by polyGA sequence are the most toxic. In this work, inhibition of aggregation of polyGA DPRs using aptamers has been explored as a therapeutic strategy to delay disease progression. Target-specific, high-affinity RNA aptamers were selected against monomeric (GA). Selected aptamers showed significant inhibition of aggregation of (GA) in vitro. Inhibitory RNA sequences were seen to form typical secondary structures which was missing in a non-inhibitory sequence. Some of the RNA aptamers showed increased solubilisation of DPRs formed by (GA) and (GA) in a neuronal cell model of ALS-FTD. Decreased aggregation was accompanied by lower oxidative stress and improved cell survival. Importantly, expression level of one of the markers of autophagy was significantly enhanced in the presence of aptamers, explaining lower aggregation observed in these cells. Thus, aptamers may be developed as potential therapeutic agents in C9 ALS-FTD.
C9ORF72基因非编码区的六核苷酸(GGGGCC)重复扩增是肌萎缩侧索硬化症-额颞叶痴呆(ALS-FTD)的主要遗传病因。通过RNA或蛋白质获得毒性功能,或通过单倍剂量不足导致功能丧失,是疾病进展的可能机制。扩增的GGGGCC重复序列编码在大脑中形成包涵体的二肽重复(DPR)蛋白。在所有二肽中,由聚GA序列形成的聚集体毒性最大。在这项研究中,探索了使用适体抑制聚GA DPRs聚集作为延缓疾病进展的治疗策略。针对单体(GA)筛选出了靶向特异性、高亲和力的RNA适体。所选适体在体外对(GA)的聚集有显著抑制作用。观察到抑制性RNA序列形成典型的二级结构,而非抑制性序列则没有。一些RNA适体在ALS-FTD神经元细胞模型中显示出由(GA)和(GA)形成的DPRs的溶解度增加。聚集减少伴随着氧化应激降低和细胞存活率提高。重要的是,在存在适体的情况下,自噬标志物之一的表达水平显著增强,这解释了在这些细胞中观察到的较低聚集现象。因此,适体可能被开发为C9 ALS-FTD的潜在治疗药物。